Amandine Gagneux-Brunon, Gagnaire Julie, Pelissier Carole, Philippe Berthelot, Elisabeth Botelho-Nevers
Inserm, CIC 1408, I-REIVAC, University Hospital of Saint-Etienne, 42055 Saint-Etienne, France.
CIRI - Centre International de Recherche en Infectiologie, Team GIMAP, Univ Lyon, Université Jean Monnet, Université Claude Bernard Lyon 1, Inserm, U1111, CNRS, UMR530, F42023 Saint-Etienne, France.
Vaccine X. 2022 May 5;11:100168. doi: 10.1016/j.jvacx.2022.100168. eCollection 2022 Aug.
In spite of the widespread implementation of preventive strategies, the prevalence of healthcare-associated infections (HAIs) remains high. The prevalence of multidrug resistant organisms is high in HAIs. In 2019, the World Health Organization retained antimicrobial resistance as one of the ten issues for global health. The development of vaccines may contribute to the fight against antimicrobial resistance to reduce the burden of HAIs. , Gram negative bacteria and are the most frequent pathogens reported in HAIs. Consequently, the development of vaccines against these pathogens is crucial. At this stage, the goal of obtaining effective vaccines against and Gram negative bacteria has not yet been achieved. However, we can expect in the near future availability of a vaccine against . In addition, identifying populations who may benefit from these vaccines is complex, as at-risk patients are not great responders to vaccines, or as vaccination may occur too late, when they are already confronted to the risk. Vaccinating healthcare workers (HCWs) against these pathogens may have an impact only if HCWs play a role in the transmission and in the pathogens acquisition in patients, if the vaccine is effective to reduce pathogens carriage and if vaccine coverage is sufficient to protect patients. Acceptance of these potential vaccines should be evaluated and addressed in patients and in HCWs.
尽管预防策略已广泛实施，但医疗保健相关感染（HAIs）的患病率仍然很高。HAIs中多重耐药菌的患病率很高。2019年，世界卫生组织将抗菌药物耐药性列为全球卫生十大问题之一。疫苗的研发可能有助于对抗抗菌药物耐药性，以减轻HAIs的负担。革兰氏阴性菌是HAIs中报告最频繁的病原体。因此，针对这些病原体研发疫苗至关重要。现阶段，尚未实现获得针对[此处原文缺失具体病原体名称]和革兰氏阴性菌的有效疫苗的目标。然而，我们预计在不久的将来会有针对[此处原文缺失具体病原体名称]的疫苗。此外，确定哪些人群可能从这些疫苗中受益很复杂，因为高危患者对疫苗的反应不佳，或者疫苗接种可能为时已晚，此时他们已经面临感染风险。只有当医护人员在病原体传播和患者病原体感染中起作用、疫苗能有效减少病原体携带且疫苗覆盖率足以保护患者时，为医护人员接种针对这些病原体的疫苗才可能产生影响。应评估患者和医护人员对这些潜在疫苗的接受度并加以解决。
